Sirtuin 6 regulates the proliferation and survival of clear cell renal cell carcinoma cells via B-cell lymphoma 2.

Sirtuin 6 () is a member of the third family of longevity proteins (SIRTs) that is involved in the development of different types of cancer. However, the potential role of in clear cell renal cell carcinoma (ccRCC) and its molecular mechanism have not yet been fully elucidated. Therefore, the present study aimed to investigate the association between SIRT6 and ccRCC, and to further examine the underlying mechanism of its effect on ccRCC proliferation, using bioinformatics analysis, and and experiments. The results of the present study demonstrated that was upregulated in ccRCC tissues. In addition, bioinformatics analysis revealed that high expression was closely associated with poor prognosis of patients with ccRCC. experiments demonstrated that silencing expression in ccRCC-derived 769-P and 786-O cells significantly inhibited their proliferation, migration and invasion. Consistent with these results, assays demonstrated that knockdown markedly attenuated tumor growth arising from 769-P cells. Furthermore, depletion of enhanced the sensitivity of ccRCC cells to cisplatin. Notably, silencing expression decreased B-cell lymphoma 2 (Bcl-2) expression and increased Bax expression, respectively. Taken together, these results suggest that acts as a proto-oncogene in ccRCC through the augmentation of the Bcl-2-dependent pro-survival pathway, and may be used as a therapeutic target for patients with ccRCC.